



JC14 Rec'd PCT/PTO 10 DEC 2001


#4
PCT

PATENT

Attorney Docket No.: 29729/37581

#4

**IN THE UNITED STATES PATENT
AND TRADEMARK OFFICE**

Applicant(s):)	I hereby certify that this paper
Atkins et al.)	is being deposited with the
Serial No.: 09/889,075)	United States Postal Service
U.S. National Phase of)	with sufficient postage as first
PCT/AU00/00011)	class mail in an envelope
Filed 01/11/00 (U.S. National Phase)	addressed to: Commissioner
entered on July 11, 2001))	for Patents, Washington, D.C.
For: Catalytic Molecules)	20231 on this date:
Group Art Unit: Not Yet Assigned)	October 19, 2001
Examiner: Not Yet Assigned)	
)	David A. Gass
)	Registration No. 38,153
)	Attorney for Applicant(s)

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

The patents and/or publications listed on the enclosed PTO Form-1449 are submitted pursuant to 37 CFR §§ 1.56, 1.97, and 1.98. The Applicants request that the documents be considered by the Examiner and made of record in the application. Copies of the listed patents or publications are enclosed. Some of the art cited on the enclosed Form-1449 was also designated in the corresponding International Search Report for PCT/AU00/00011. A copy of the International Search Report has been included.

TIME OF FILING

This information disclosure statement is being filed:


- ☒ 1. with the application or within three months of the filing date of the application or date of entry into the national stage of an international application or, to the best of the undersigned's knowledge, before the mailing date of a first Office Action on the merits, whichever event occurs last. In accordance with 37 CFR §1.97(b), no certification or fee is required.

The Commissioner is authorized to charge any fee deficiency required by this paper, or credit any overpayment, to Deposit Account No. 13-2855. A copy of this paper is enclosed.

Respectfully submitted,

MARSHALL, GERSTEIN & BORUN
6300 Sears Tower
233 South Wacker Drive
Chicago, Illinois 60606-6357
(312) 474-6300

By:


David A. Gass
Reg. No: 38,153

October 19, 2001


Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
29729/37581Serial No.
09/889,075

INFORMATION DISCLOSURE STATEMENT

Applicant
Atkins et al.Filing Date
01/11/00Group
Not yet assigned

(Use several sheets if necessary)



FOREIGN PATENT DOCUMENTS

*Examiner Initials		Document Number	Publication Date	Country	Class	Subclass	Translation	
							Yes	No
	B1	WO 96/17086	06/06/96	PCT				
	B2	WO 97/32979	09/12/97	PCT				
	B3	WO 98/49346	11/05/98	PCT				
	B4	WO 99/50452	10/07/99	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

	C1	Cairns <i>et al.</i> , "Target Site Selection for an RNA-Cleaving Catalytic DNA" <i>Nature Biotechnology</i> , Vol. 17, pp. 480-486, May 1999
	C2	Milbrandt, J. Rat nerve growth factor-induced (NGFI-A) gene complete cds. 1987. Genbank Accession No. M18416
	C3	Santiago <i>et al.</i> , "New DNA Enzyme Targeting Egr-1 mRNA Inhibits Vascular Smooth Muscle Proliferation and Regrowth After Injury" <i>Nature Medicine</i> ; Vol. 5, No. 11, pp. 1264-1269, November 1999
	C4	Santoro <i>et al.</i> , "Mechanism and Utility of an RNA-Cleaving DNA Enzyme" <i>Biochemistry</i> , Vol. 37, No. 38, pp. 13330-13342, 1998
	C5	Santoro <i>et al.</i> , "A General Purpose RNA-Cleaving DNA Enzyme" <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 94, pp. 4262-4266, April 1997
	C6	Sukhatme, V.P. Human mRNA for early growth response Protein 1 (hEGR1). 1990. Genbank Accession No. X52541

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.